Miltefosine: issues to be addressed in the future

被引：33

作者：

Berman, J.

Bryceson, A. D. M.

Croft, S.

Engel, J.

Gutteridge, W.

Karbwang, J.

Sindermann, H.

Soto, J.

Sundar, S.

Urbina, J. A.

机构：

[1] London Sch Hyg & Trop Med, London WC1E 7HT, England

[2] DNDi, CH-1201 Geneva, Switzerland

[3] Zentaris GmbH, D-60314 Frankfurt, Germany

[4] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland

[5] Consorcio Invest Bioclin, Bogota, Colombia

[6] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India

[7] Inst Venezolano Invest Cient, Ctr Biofis & Bioquim, Lab Quim Biol, Caracas 1020A, Venezuela

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2006年 / 100卷

关键词：

visceral leishmaniasis; cutaneous leishmaniasis; mucosal leishmaniasis; miltefosine; resistance; toxicity;

D O I：

10.1016/j.trstmh.2006.02.009

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions. (c) 2006 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

引用

收藏

页码：S41 / S44

页数：4

相关论文

共 20 条

[1] A policy for leishmaniasis with respect to the prevention and control of drug resistance [J].

Bryceson, A .

TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (11) :928-934

[2] Dihidro-β-agarofuran sesquiterpenes:: A new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania [J].

Cortés-Selva, F ;

Jiménez, IA ;

Muñoz-Martínez, F ;

Campillo, M ;

Bazzocchi, IL ;

Pardo, L ;

Ravelo, AG ;

Castanys, S ;

Gamarro, F .

CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (24) :3125-3139

[3] Functional expression of a multidrug P-glycoprotein transporter of Leishmania [J].

Cortés-Selva, F ;

Muñoz-Martínez, F ;

Iliás, A ;

Jiménez, AI ;

Váradi, A ;

Gamarro, F ;

Castanys, S .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (02) :502-507

[4] Antiprotozoal lysophospholipid analogues: A comparison of their activity against trypanosomatid parasites and tumor cells [J].

de Castro, SL ;

Santa-Rita, RM ;

Urbina, JA ;

Croft, SL .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (02) :141-151

[5] Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B [J].

Escobar, P ;

Matu, S ;

Marques, C ;

Croft, SL .

ACTA TROPICA, 2002, 81 (02) :151-157

[6] Miltefosine - The long-awaited therapy for visceral leishmaniasis? [J].

Herwaldt, BL .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (24) :1840-1842

[7] Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi:: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole [J].

Lira, R ;

Contreras, LM ;

Rita, RMS ;

Urbina, JA .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (05) :537-546

[8] Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance [J].

Muñoz-Martínez, F ;

Lu, PH ;

Cortés-Selva, F ;

Pérez-Victoria, JM ;

Jiménez, IA ;

Ravelo, AG ;

Sharom, FJ ;

Gamarro, F ;

Castanys, S .

CANCER RESEARCH, 2004, 64 (19) :7130-7138

[9] Functional cloning of the miltefosine transporter -: A novel P-type phospholipid translocase from Leishmania involved in drug resistance [J].

Pérez-Victoria, FJ ;

Gamarro, F ;

Ouellette, M ;

Castanys, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) :49965-49971

[10] Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug [J].

Pérez-Victoria, FJ ;

Castanys, S ;

Gamarro, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2397-2403